Elevated lipoprotein-associated phospholipase A2 in geriatric patients

Czech version

Authors: MUDr. Jo O Fortunato ¹; MUDr. Michaela Fortunato ¹; prof. MUDr. Vladimír Blaha, CSc. ¹; MUDr. Josef Bis, Ph.D. ²; doc. RNDr. Ctirad Andrýs, Ph.D. ³; MUDr. Božena Jurašková, Ph.D. ¹; prof. MUDr. Luboš Sobotka, CSc. ¹
Authors‘ workplace: III. interní gerontometabolická klinika, FN Hradec Králové ¹; I. interní karioangiologická klinika, FN Hradec Králové ²; Ústav klinické imunologie a alergologie, FN Hradec Králové ³
Published in: Geriatrie a Gerontologie 2020, 9, č. 2: 97-100
Category: Original Article

Overview

Lipoprotein-associated phospholipase A2 (Lp-PLA₂) is extensively expressed by advanced atherosclerotic lesions and may play a role in plaque instability. We selected a group of elderly subjects that underwent transcatheter aortic valve implantation (TAVI) or balloon angioplasty (BA) and separated them into two groups, diabetic and nondiabetic, to compare the level of Lp-PLA₂ mass between them.

Methods: 44 patients aged 79.6 ± 5.6 years with symptomatic severe aortic valve stenosis underwent TAVI (n = 35) or BA (n = 9). 21 subjects had confirmed type 2 diabetes mellitus. Lp-PLA₂ mass was measured using an enzyme- linked immunosorbent assay kit (USCN Life Science, China) before and 3 days after the procedure.

Results: Lp-PLA₂ mass was significantly elevated in this population (1296 ± 358 ng/mL before TAVI; 1413 ± 268 ng/mL before BA) and further increased after TAVI (1604 ± 437 ng/mL, P < 0.01) or BA (1808 ± 303 ng/mL, P < 0.01). Lp-PLA₂ mass was significantly increased on the diabetic group before these interventions.

Conclusion: Lp-PLA₂ may be a novel biomarker for the presence of rupture-prone atherosclerotic lesions in elderly patients. Levels of Lp-PLA₂ in diabetic patients may accompany the higher amount of small dense LDL particles seen in these subjects.

Keywords:

Atherosclerosis – diabetes mellitus – transcatheter implantation – Aortic valve – aortic stenosis – balloon angioplasty – Lipoprotein associated phospholipase

Sources

1. Mallat Z, Lambeau G, Tedgui A. “Lipoprotein-associated and secreted phospholipases A2 in cardiovascular disease: roles as biological effectors and biomarkers,” Circulation, vol. 122, no. 21, pp. 2183–2200, 2010.

2. Hui DY. “Phospholipase A2 enzymes in metabolic and cardiovascular diseases,” Current Opinion in Lipidology, vol. 23, no. 3, pp. 235–240, 2012.

3. Caslake MJ, Packard CJ. “Lipoprotein-associated phos- pholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease,” Current Opinion in Lipidology, vol. 14, no. 4, pp. 347–352, 2003.

4. Stafforini DM. “Biology of platelet-activating factor acetyl- hydrolase (PAF-AH, lipoprotein associated phospholipase A2 ),” Cardiovascular Drugs and Therapy, vol. 23, no. 1, pp. 73–83, 2009.

5. Macphee CH, Nelson JJ, Zalewski A. “Lipoprotein- associated phospholipase A2 as a target of therapy,” Current Opinion in Lipidology, vol. 16, no. 4, pp. 442–446, 2005.

6. Zalewski A, Macphee C. “Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 5, pp. 923–931, 2005.

7. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. “Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma,” Clinical Chemistry, vol. 51, no. 12, pp. 2264–2273, 2005.

8. Nishikawa T, Edelstein D, Du XL, et al. “Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage,” Nature, vol. 404, no. 6779, pp. 787– 790, 2000.

9. Wilensky RL, Macphee CH. “Lipoprotein-associated phospholipase A2 and atherosclerosis,” Current Opinion in Lipidology, vol. 20, no. 5, pp. 415–420, 2009.

10. Gorelick PB. “Lipoprotein-associated phospholipase A2 and risk of stroke,” The American Journal of Cardiology, vol. 101, no. 12A, pp. 34F–40F, 2008.

11. Colley KJ, Wolfert RL, Cobble ME. “Lipoprotein associated phospholipase A2: role in atherosclerosis and utility as a biomarker for cardiovascular risk,” The EPMA Journal, vol. 2, no. 1, pp. 27–38, 2011.

12. Noto H, Chitkara P, Raskin P. “The role of lipoprotein- associated phospholipase A2 in the metabolic syndrome and diabetes,” Journal of Diabetes and Its Complications, vol. 20, no. 6, pp. 343–348, 2006.

13. Corsetti JP, Ryan D, Moss AJ, Rainwater DL, Zareba W, Sparks CE. “Glycoprotein Ib polymorphism T145M, elevated lipoprotein-associated phospholipase A2, and hyper- triglyceridemia predict risk for recurrent coronary events in diabetic postinfarction patients,” Diabetes, vol. 56, no. 5, pp. 1429–1435, 2007.

14. Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ. “The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellituss,” Cardiovascular Diabetology, vol. 11, article 109, 2012.

15. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C. “Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 2, pp. e13–e18, 2004.